|
|
Volume 6, Issue 5, May 1999, in PDF
|
   |
Article 122: The Ups and Downs of SMO Usage
- SMO usage is growing steadily. However, sponsor and CROs are primarily using SMOs to gain access to top sites.
- SMOs appear to be outperforming independent sites in study initiation. But SMOs are more expensive.
Article 123: A New Market in Long Term Care
- The FDA's Geriatric Use Labeling Rule will require drug labeling information for patients aged 65 and over to be phase in over a six-year period. As a result, the need for clinical research among the elderly is expected to grow rapidly.
- A number of progressive nursing homes with strong links to university medical centers are leading the way in clinical trials among the elderly. Several large players, including Omnicare-IBAH have now moved into this market.
Article 124: Eye On Osteoporosis
- The treatment and prevention of osteoporosis is an extremely active therapeutic area. CenterWatch editorial estimates that $100 to $150 million in grants will be spent in this area in 1999.
Price: $59.00
|
|
|
